Tritrp-P5A

General Information


DRACP ID  DRACP00959

Peptide Name   Tritrp-P5A

Sequence  VRRFAWWWPFLRR

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  porcine cathelicidin peptide

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Jurkat Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia Leukemia IC50=16.2 µM MTT assay 24h 1

Hemolytic Activity  RBC: IC50 ≥ 65 µM

Normal (non-cancerous) Cytotoxicity  PBMC: IC50=26.4 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  2I1H 

Predicted Structure  DRACP00959

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C94H130N28O14

Absent amino acids  CDEGHIKMNQSTY

Common amino acids  R

Mass  209045

Pl  12.98

Basic residues  4

Acidic residues  0

Hydrophobic residues  8

Net charge  4

Boman Index  -3596

Hydrophobicity  -53.08

Aliphatic Index  60

Half Life 
  Mammalian: 100 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  16500

Absorbance 280nm  1375

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 32126228

Title  Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin

Doi 10.1016/j.bbamem.2020.183228

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.